Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi To Test Arthritis Drug Kevzara For Coronavirus

'Scientific Rationale' Behind Regeneron-partnered IL-6 Inhibitor

Executive Summary

The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.

You may also be interested in...



Coronavirus Hasn’t Sparked CURE ID Physician Social Network Interest

US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.

India Coronavirus Actions: Stock Checks, Kaletra Gx Readiness And Bulk Drugs

A string of actions to ensure medicines security and prioritize bulk drug project clearances are underway in India as the country enters a critical phase in its efforts to contain coronavirus cases.

Sanofi And Regeneron Initiate 400-Patient Coronavirus Trial With Kevzara

The Phase II/III trial will begin enrolling patients in the US immediately, with Regeneron taking the lead in US development and Sanofi leading ex-US trials. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel